                         SEQUENCE LISTING

<110>  The Board of Trustees of the University of Illinois
       Ackerman, Steven J.
 
<120>  Peptide Inhibition of CCR3-Mediated Diseases or Conditions

<130>  UIC0054WO

<150>  US 62/115,880
<151>  2015-02-13

<160>  24    

<170>  PatentIn version 3.5

<210>  1
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  1

Leu Leu Phe Leu Val Thr Leu Pro Phe Trp Ile His Tyr Val Arg Gly 
1               5                   10                  15      


His Asn Trp Val Phe Gly Asp Asp Asp 
            20                  25  


<210>  2
<211>  28
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  2

Phe Gly Val Ile Thr Ser Ile Val Thr Trp Gly Leu Ala Val Leu Ala 
1               5                   10                  15      


Ala Leu Pro Glu Phe Ile Phe Tyr Glu Thr Glu Asp 
            20                  25              


<210>  3
<211>  28
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa denotes Thr or Ile

<400>  3

Ile Phe Val Xaa Met Ala Val Phe Phe Ile Phe Trp Thr Pro Tyr Asn 
1               5                   10                  15      


Val Ala Ile Leu Leu Ser Ser Tyr Gln Ser Asp Asp 
            20                  25              


<210>  4
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  4

Asp Asp Leu Val Met Leu Val Thr Glu Val Ile Ala Tyr Ser His Cys 
1               5                   10                  15      


Cys Met Asn Pro Val Ile Tyr Ala Phe Val 
            20                  25      


<210>  5
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  5

Leu Leu Asn Leu Ala Ile Ser Asp Leu Leu Phe Leu Val Thr Leu Pro 
1               5                   10                  15      


Phe Trp Ile His Tyr Val Arg Gly His Asn Trp Val Phe Gly His 
            20                  25                  30      


<210>  6
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  6

Leu Leu Asn Leu Ala Ile Ser Asp Leu Leu Phe Leu Phe Thr Leu Pro 
1               5                   10                  15      


Phe Trp Ile His Tyr Val Arg Gly His Asn Trp Val Phe Gly His 
            20                  25                  30      


<210>  7
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  7

Leu Leu Asn Leu Ala Ile Ser Asp Leu Leu Phe Leu Phe Thr Leu Pro 
1               5                   10                  15      


Phe Trp Ile His Tyr Val Arg Glu Arg Asn Trp Val Phe Ser His 
            20                  25                  30      


<210>  8
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  8

Leu Leu Asn Leu Ala Ile Ser Asp Leu Leu Phe Leu Phe Thr Leu Val 
1               5                   10                  15      


Phe Trp Ile His Tyr Thr Gly Trp Asn Asp Trp Val Phe Gly Arg 
            20                  25                  30      


<210>  9
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  9

Leu Leu Asn Leu Ala Ile Ser Asp Val Leu Phe Leu Phe Thr Leu Pro 
1               5                   10                  15      


Phe Trp Ile His Tyr Val Arg Trp Asn Glu Trp Val Phe Gly His 
            20                  25                  30      


<210>  10
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  10

Leu Phe Asn Leu Ala Ile Ser Asp Leu Leu Phe Leu Phe Thr Val Pro 
1               5                   10                  15      


Phe Trp Ile His Tyr Val Leu Trp Asn Glu Trp Gly Phe Gly His 
            20                  25                  30      


<210>  11
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  11

Leu Leu Asn Leu Ala Ile Ser Asp Leu Leu Phe Leu Phe Thr Val Pro 
1               5                   10                  15      


Phe Trp Ile His Tyr Val Leu Trp Asn Glu Trp Gly Phe Gly His 
            20                  25                  30      


<210>  12
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  12

Leu Phe Asn Leu Ala Ile Ser Asp Leu Leu Phe Leu Phe Thr Leu Pro 
1               5                   10                  15      


Phe Trp Ile His Tyr Ile Leu Arg Lys Glu Trp Gly Phe Gly His 
            20                  25                  30      


<210>  13
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  13

Leu Phe Asn Leu Ala Ile Ser Asp Leu Leu Phe Leu Phe Thr Leu Pro 
1               5                   10                  15      


Phe Trp Ile His Tyr Val Arg Trp Asn Glu Trp Val Phe Asp Ser 
            20                  25                  30      


<210>  14
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa denotes Leu or Phe

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Xaa denotes Leu or Val

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  Xaa denotes Phe or Val

<220>
<221>  MISC_FEATURE
<222>  (15)..(15)
<223>  Xaa denotes Leu or Val

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa denotes Pro or Val

<220>
<221>  MISC_FEATURE
<222>  (22)..(22)
<223>  Xaa denotes Ile, Thr or Val

<220>
<221>  MISC_FEATURE
<222>  (23)..(23)
<223>  Xaa denotes Arg, Gly or Leu

<220>
<221>  MISC_FEATURE
<222>  (24)..(24)
<223>  Xaa denotes Trp, Gly, Glu or Arg

<220>
<221>  MISC_FEATURE
<222>  (25)..(25)
<223>  Xaa denotes His, Arg, Asn or Lys

<220>
<221>  MISC_FEATURE
<222>  (26)..(26)
<223>  Xaa denotes Asn, Asp or Glu

<220>
<221>  MISC_FEATURE
<222>  (28)..(28)
<223>  Xaa denotes Val or Gly

<220>
<221>  MISC_FEATURE
<222>  (30)..(30)
<223>  Xaa denotes Gly, Ser or Asp

<220>
<221>  MISC_FEATURE
<222>  (31)..(31)
<223>  Xaa denotes His, Arg or Ser

<400>  14

Leu Xaa Asn Leu Ala Ile Ser Asp Xaa Leu Phe Leu Xaa Thr Xaa Xaa 
1               5                   10                  15      


Phe Trp Ile His Tyr Xaa Xaa Xaa Xaa Xaa Trp Xaa Phe Xaa Xaa 
            20                  25                  30      


<210>  15
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa denotes Leu or Val

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa denotes Phe or Val

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa denotes Leu or Val

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa denotes Pro or Val

<400>  15

Xaa Leu Phe Leu Xaa Thr Xaa Xaa Phe Trp Ile His Tyr 
1               5                   10              


<210>  16
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  16

Leu Leu Phe Leu Val Thr Leu Pro Phe Trp Ile His Tyr 
1               5                   10              


<210>  17
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  17

Leu Leu Asn Leu Ala Ile Ser Asp Leu Leu Phe Leu Val Thr Leu Pro 
1               5                   10                  15      


Phe Trp Ile His Tyr 
            20      


<210>  18
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  18

Leu Leu Phe Leu Val Thr Leu Pro Phe Trp Ile His Tyr Val Arg Gly 
1               5                   10                  15      


His Asn Trp Val Phe Gly His 
            20              


<210>  19
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  19

Leu Leu Asn Leu Ala Ile Ser Asp Leu Leu Phe Leu Val Thr Leu Pro 
1               5                   10                  15      


Phe Trp Ile His Tyr Asp Asp Asp Cys 
            20                  25  


<210>  20
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  20

Leu Leu Phe Leu Val Thr Leu Pro Phe Trp Ile His Tyr Val Arg Gly 
1               5                   10                  15      


His Asn Trp Val Phe Gly His Asp Asp Asp 
            20                  25      


<210>  21
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (26)..(26)
<223>  PEGylation and amidation.

<400>  21

Leu Leu Phe Leu Val Thr Leu Pro Phe Trp Ile His Tyr Val Arg Gly 
1               5                   10                  15      


His Asn Trp Val Phe Gly His Asp Asp Asp 
            20                  25      


<210>  22
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  22

Leu Leu Phe Leu Val Thr Leu Pro Phe Trp Ile His Tyr Val Arg Gly 
1               5                   10                  15      


His Asn Trp Val Phe Gly His Asp Asp Asp Cys 
            20                  25          


<210>  23
<211>  24
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (24)..(24)
<223>  PEGylation and amidation

<400>  23

Leu Leu Asn Leu Ala Ile Ser Asp Leu Leu Phe Leu Val Thr Leu Pro 
1               5                   10                  15      


Phe Trp Ile His Tyr Asp Asp Asp 
            20                  


<210>  24
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (26)..(26)
<223>  PEGylation and amidation.

<400>  24

Tyr Leu Phe Leu Leu Val Thr Val Phe His Ile Trp Leu Pro His Asn 
1               5                   10                  15      


Arg Gly His Val Trp Gly Phe Asp Asp Asp 
            20                  25      


